Skip to content
MONTEGRE

Daily pill eradicates advanced pancreatic cancer in some patients

A once-daily drug combined with chemotherapy eliminated advanced pancreatic cancer in one in 12 patients, according to trial results.

Sources: Metro, Gulf News, Habertürk Ekonomi, Ghana Broadcasting Corporation4 sources ↓|· 1 min read
Daily pill eradicates advanced pancreatic cancer in some patients
Photo: Metro

KEY POINTS

  • One in 12 patients had advanced pancreatic cancer completely eradicated
  • Tumours shrank or disappeared in 60.7 percent of patients receiving the drug plus chemotherapy
  • Disease control rate was 90.2 percent across all 61 patients studied
  • One-year survival was 76.6 percent versus 40 to 45 percent with chemotherapy alone
  • Daraxonrasib targets the mutated KRAS gene found in most pancreatic tumours

A new once-a-day pill has wiped out advanced pancreatic cancer in some patients, marking a major treatment breakthrough. The drug, daraxonrasib, was used alongside chemotherapy in a clinical trial.

One in 12 patients had their advanced cancer completely eradicated, meaning their tumours were no longer detectable after treatment.

“The results represent the closest thing to a cure for some patients.”

— the lead medic on the trial

In the study of 61 patients, tumours shrank or disappeared in 60.7 percent of those given daraxonrasib and chemotherapy. Complete responses were seen in 8.2 percent of patients over a typical follow-up of 18 months.

Overall, the disease stopped growing in 90.2 percent of all patients studied over the same period. One year after treatment, 76.6 percent of patients were still alive, compared with around 40 to 45 percent for chemotherapy alone.

Daraxonrasib works by locking onto the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumours and signals cancer cells to grow. By shutting this off, the drug can prevent tumours from spreading.

The pill also caused fewer side effects than standard treatment. In May, research showed the drug could almost double survival time for patients with aggressive and advanced pancreatic cancer compared with chemotherapy alone.

READ THE FULL STORYat Metro

3 more sources below

COMMENTS (0)

0/2000

No comments yet. Be the first.

RELATED STORIES

This page was compiled with AI assistance from the outlets named above and passed an automated language check before publication. Montegre has no reporters of its own; the byline names the outlets the story was compiled from. Method and editorial standards